TCM
TRIB

Triumph Capital Management’s Trinity Biotech TRIB Stock Holding History

Triumph Capital Management’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-33
Closed -$542 – 1917
2026
Q1 		$542 Hold
33
– – ﹤0.01% 1694
2025
Q4 		$791 Buy
+33
New +$973 ﹤0.01% 1599

Other funds holding TRIB

HAIM
Hunter Associates Investment Management Pittsburgh, Pennsylvania $868M AUM 32.25% 1-Year Est. Return
WN
Williams & Novak Westlake Village, California $151M AUM 27.43% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
MAWA
Moss Adams Wealth Advisors Seattle, Washington $1.6B AUM 28.24% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
BCM
Becker Capital Management Portland, Oregon $3.72B AUM 31.98% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Triumph Capital Management's TRIB Position: Q2 2026 in Review

Triumph Capital Management sold out of Trinity Biotech (TRIB) in Q2 2026, closing a stake of 33 shares — an estimated $542 sold.

Triumph Capital Management first reported a position in TRIB in Q4 2025 and held it in 2 quarters. The position peaked at $791 in Q4 2025. 19 funds tracked by Wall St. Rank hold TRIB as of Q2 2026.

  • Triumph Capital Management reported no remaining Trinity Biotech position as of Q2 2026 after selling out during the quarter.
  • Triumph Capital Management sold 33 Trinity Biotech shares in Q2 2026, an estimated $542.
  • Triumph Capital Management first reported a position in Trinity Biotech in Q4 2025 and held it in 2 quarters.
  • Triumph Capital Management's Trinity Biotech position peaked at $791 in Q4 2025.
  • 19 funds tracked by Wall St. Rank held Trinity Biotech as of Q2 2026.

Based on Triumph Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.